Related Experiment Videos
Prognostic factors in mesothelioma
Jeremy P C Steele1, Astero Klabatsa, Dean A Fennell
1Mesothelioma Unit, Department of Medical Oncology, St. Bartholomew's Hospital and Medical College, London EC1A 7BE, UK. jeremy.steele@bartsandthelondon.nhs.uk
Lung Cancer (Amsterdam, Netherlands)
|May 17, 2005
Summary
Identifying key prognostic factors is crucial for mesothelioma treatment decisions. Poor performance status, non-epithelioid histology, and elevated LDH are significant predictors of poor prognosis in mesothelioma patients.
Area of Science:
- Oncology
- Clinical Medicine
- Biostatistics
Background:
- Prognostic factors aid treatment planning for mesothelioma patients.
- Mesothelioma lacks a universally applicable anatomical staging system.
- Existing staging systems (IMIG, Brigham) have limited relevance without surgery.
Purpose of the Study:
- To identify and validate key prognostic factors for mesothelioma.
- To improve treatment decision-making for mesothelioma patients.
- To assess the predictive value of established prognostic models.
Main Methods:
- Review of prognostic scoring systems (EORTC, CALGB).
- Validation of the EORTC model in a cohort of 145 mesothelioma patients.
- Analysis of survival data for patients treated with vinorelbine.
Main Results:
- Key predictors of poor prognosis include poor performance status, non-epithelioid histology, male gender, low hemoglobin, high platelet count, high white blood cell count, and high lactate dehydrogenase (LDH).
- The EORTC model showed significant survival differences: 19.2 months for the best prognostic group vs. 9.9 months for the worst group in vinorelbine-treated patients.
- Radiological prediction of staging is of limited value.
Conclusions:
- Established prognostic factors significantly impact survival in mesothelioma.
- Prospective recording of clinical and biological factors is recommended for mesothelioma patients in clinical trials.
- Accurate prognostication can guide personalized treatment strategies for mesothelioma.